These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33662689)

  • 1. DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients.
    Schotten LM; Darwiche K; Seweryn M; Yildiz V; Kneuertz PJ; Eberhardt WEE; Eisenmann S; Welter S; Sisson BE; Pietrzak M; Wiesweg M; Ploenes T; Hager T; He K; Freitag L; Aigner C; Taube C; Oezkan F
    Eur J Cancer; 2021 Apr; 147():142-150. PubMed ID: 33662689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [DNA methylation detection of SHOX2 and PTGER4 in plasma contributes to differential diagnosis of pulmonary nodule patients].
    Chu X; Zhao W; Wang B
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Apr; 35(4):357-361. PubMed ID: 31167696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
    Xing W; Sun H; Yan C; Zhao C; Wang D; Li M; Ma J
    BMC Cancer; 2021 Mar; 21(1):263. PubMed ID: 33691657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer.
    Huang W; Huang H; Zhang S; Wang X; Ouyang J; Lin Z; Chen P
    Cancer Control; 2020; 27(1):1073274820969703. PubMed ID: 33167712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.
    Weiss G; Schlegel A; Kottwitz D; König T; Tetzner R
    J Thorac Oncol; 2017 Jan; 12(1):77-84. PubMed ID: 27544059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
    Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
    J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
    Li X; Zhang Q; Jin X; Cao L
    World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
    Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
    J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinically effective model based on cell-free DNA methylation and low-dose CT for risk stratification of pulmonary nodules.
    Liang W; Tao J; Cheng C; Sun H; Ye Z; Wu S; Guo Y; Zhang J; Chen Q; Liu D; Liu L; Tian H; Teng L; Zhong N; Fan JB; He J
    Cell Rep Med; 2024 Oct; 5(10):101750. PubMed ID: 39341207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study.
    Li Y; Xie F; Zheng Q; Zhang Y; Li W; Xu M; He Q; Li Y; Sun J
    Lung Cancer; 2024 Sep; 195():107930. PubMed ID: 39146624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
    Kossenkov AV; Qureshi R; Dawany NB; Wickramasinghe J; Liu Q; Majumdar RS; Chang C; Widura S; Kumar T; Horng WH; Konnisto E; Criner G; Tsay JJ; Pass H; Yendamuri S; Vachani A; Bauer T; Nam B; Rom WN; Showe MK; Showe LC
    Cancer Res; 2019 Jan; 79(1):263-273. PubMed ID: 30487137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of lung malignant epithelial cells by gene methylation analysis in the conditionally reprogrammed cell cultures.
    Wu GD; Xiao YG; Fang FY; Yao D; Liu J; Cao YH; Mao Y; Yu B; Yao TR; Wu YM; Qian YH; Yu DH
    Neoplasma; 2020 May; 67(3):692-699. PubMed ID: 32202907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of SHOX2 methylation test in peripheral blood samples used for the differential diagnosis of lung cancer and other lung disorders.
    Konecny M; Markus J; Waczulikova I; Dolesova L; Kozlova R; Repiska V; Novosadova H; Majer I
    Neoplasma; 2016; 63(2):246-53. PubMed ID: 26774146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision patient selection for improved detection of circulating genetically abnormal cells in pulmonary nodules.
    Tu M; Wang X; Liu H; Jia H; Wang Y; Li J; Zhang G
    Sci Rep; 2024 Sep; 14(1):22532. PubMed ID: 39341939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules.
    Liu QX; Zhou D; Han TC; Lu X; Hou B; Li MY; Yang GX; Li QY; Pei ZH; Hong YY; Zhang YX; Chen WZ; Zheng H; He J; Dai JG
    Adv Sci (Weinh); 2021 Jul; 8(13):2100104. PubMed ID: 34258160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Combination of SHOX2 and RASSF1A DNA Methylation Had a Diagnostic Value in Pulmonary Nodules and Early Lung Cancer.
    Xie B; Dong W; He F; Peng F; Zhang H; Wang W
    Oncology; 2024; 102(9):759-774. PubMed ID: 38262380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative diagnosis of malignant pulmonary nodules in lung cancer screening with a radiomics nomogram.
    Liu A; Wang Z; Yang Y; Wang J; Dai X; Wang L; Lu Y; Xue F
    Cancer Commun (Lond); 2020 Jan; 40(1):16-24. PubMed ID: 32125097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules.
    Lin Y; Leng Q; Jiang Z; Guarnera MA; Zhou Y; Chen X; Wang H; Zhou W; Cai L; Fang H; Li J; Jin H; Wang L; Yi S; Lu W; Evers D; Fowle CB; Su Y; Jiang F
    Int J Cancer; 2017 Sep; 141(6):1240-1248. PubMed ID: 28580707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The performance of the
    Xu Z; Wang Y; Wang L; Xiong J; Wang H; Cui F; Peng H
    Biomark Med; 2020 Apr; 14(5):341-351. PubMed ID: 32250153
    [No Abstract]   [Full Text] [Related]  

  • 20. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma.
    Kneip C; Schmidt B; Seegebarth A; Weickmann S; Fleischhacker M; Liebenberg V; Field JK; Dietrich D
    J Thorac Oncol; 2011 Oct; 6(10):1632-8. PubMed ID: 21694641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.